REVIEW – June 2020

Myasthenia

Authors: Liis Sabre, Maarika Liik

Articles PDF Visible only to registered users

Abstract

Myasthenia gravis (MG) is an autoimmune disease with fluctuating muscle weakness and fatigue. Treatment depends on patient age at presentation, gender, thymic abnormality, antibody profile and severity of symptoms. Treatment can be divided into two classes, symptomatic and immunosuppressive, and is effective in the majority of MG patients. Weakness varies over longer period and is influenced by stress and infection, as well as by immunological or hormonal factors or operations. Better knowledge of the pathogenesis and treatment of the disease have has led us to a more personalized treatment that can improve the patients’ quality of life.